Codexis's fundamental outlook is clouded by revenue that swings from $7.5M to $38.9M per quarter, with the 2025Q4 spike appearing to be an outlier rather than a durable trend, while operating margin was -75.3% in 2026Q2.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 11, 2026 | -$0.13+8.2% vs -$0.14 | $15M+7.9% vs $14M |
Q2 2026 May 7, 2026 | -$0.10+9.1% vs -$0.11 | $15M+5.0% vs $15M |
Q2 2026 Mar 11, 2026 | $0.11+1000.0% vs $0.01 | $39M+8.6% vs $36M |
Q4 2025 Nov 6, 2025 | -$0.22-46.7% vs -$0.15 | $9M-76.0% vs $36M |
REDWOOD CITY, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced that it will report its financial results for the third quarter of 2026 on Thursday, November 12, 2026, following the close of market.
REDWOOD CITY, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Codexis , Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced an agreement with a pioneering siRNA drug innovator to explore stereo-defined fragment synthesis using its ECO Synthesis® Manufacturing Platform.
Revvity (NYSE: RVTY - Get Free Report) and Codexis (NASDAQ: CDXS - Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, institutional ownership and risk. Institutional and Insider Ownership 86.7% of Revvity shares are held
Mettler-Toledo International (NYSE: MTD - Get Free Report) and Codexis (NASDAQ: CDXS - Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, profitability and analyst recommendations. Volatility and Risk Mettler-Toledo International has a beta of
Benchmark CDXS against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Codexis, Inc. (CDXS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.08 | $116.17M | -3.20 | 18.61% | -39.55% | -74.36% | — | |
| $1.39 | $338.34M | -1.55 | 849.33% | -119.93% | -50.64% | — | |
| $26.41 | $2.72B | -25.82 | 120.01% | -73.04% | -9.69% | — | |
| $44.64 | $2.62B | 11.03 | 77.36% | 30.01% | 11.1% | 2.16% | |
| $4.16 | $1.44B | -10.77 | 698.96% | -67.38% | -49.11% | — | |
| $2.38 | $259.88M | -15.80 | — | — | -5.76% | — |
Codexis, Inc. (CDXS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Codexis, Inc. (CDXS) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 11, 2026·SEC
Jul 27, 2026·SEC
Jul 23, 2026·SEC
Get notified when CDXS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Codexis, Inc. (CDXS) stock FAQ — growth, dividends, profitability & financials explained
Codexis, Inc. (CDXS) reported $77.7M in revenue over the trailing twelve months. Revenue was $70.4M in fiscal year 2025. That is 480% more than the $12.1M of fiscal year 2006.
Codexis, Inc. (CDXS) grew revenue by 35.9% over the trailing twelve months, compared with the twelve months before.
No. Codexis, Inc. (CDXS) reported a net loss of $30.7M over the trailing twelve months.
Codexis, Inc. (CDXS) had a return on equity (ROE) of -74.4% over the trailing twelve months. A negative ROE means the company lost money over the period.
Codexis, Inc. (CDXS) had negative free cash flow of $12.2M over the trailing twelve months.
